Management of microscopic colitis: challenges and solutions
Open Access
- 1 February 2019
- journal article
- review article
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. ume 12, 111-120
Abstract
Microscopic colitis (MC) is a chronic inflammatory bowel disease characterized by nonbloody diarrhea in the setting of normal appearing colonic mucosa. MC has two main subtypes based on histopathologic features, collagenous colitis and lymphocytic colitis. Management of both subtypes is the same, with treatment goal of reducing the number of bowel movements and improving consistency. First-line treatment involves counseling the patient about decreasing their risk factors, like discontinuing smoking and avoiding medications with suspected association such as NSAIDs, proton pump inhibitor, ranitidine, and sertraline. Starting loperamide for immediate symptomatic relief is used as an adjunct to therapy with glucocorticoids. Budesonide is considered first-line treatment for MC given its favorable side effect profile and good efficacy, though relapse rates are high. Systemic glucocorticoids should be reserved to patients unable to take budesonide. In glucocorticoid refractory disease, medications that have been tried include cholestyramine, bismuth salicylate, antibiotics, probiotics, aminosalicylates, immunomodulators, and anti-tumor necrosis factor-alpha inhibitors. More research is needed for the creation of a systematic stepwise approach for relapsing and refractory disease.Keywords
This publication has 79 references indexed in Scilit:
- Lack of effect of methotrexate in budesonide-refractory collagenous colitisClinical and Experimental Gastroenterology, 2013
- Auto-Antibodies and Their Association with Clinical Findings in Women Diagnosed with Microscopic ColitisPLOS ONE, 2013
- Human leucocyte antigen and TNFα polymorphism association in microscopic colitisEuropean Journal of Gastroenterology & Hepatology, 2008
- Collagenous colitis: Oral low‐dose methotrexate for patients with difficult symptoms: Long‐term outcomesJournal of Gastroenterology and Hepatology, 2007
- Metabolic and inflammatory faecal markers in collagenous colitisEuropean Journal of Gastroenterology & Hepatology, 2007
- Mesalazine with or without cholestyramine in the treatment of microscopic colitis: Randomized controlled trialJournal of Gastroenterology and Hepatology, 2006
- The ProbioticE. coliStrain Nissle 1917 for the Treatment of Collagenous Colitis: First Results of an Open-Label TrialZeitschrift für Gastroenterologie, 2004
- Lymphocytic Colitis Treated with Proctocolectomy and Ileal J-Pouch-Anal AnastomosisDiseases of the Colon & Rectum, 2002
- Budesonide (Entocort?? EC Capsules)*Drugs, 2002
- Role of bile acids and bile acid binding agents in patients with collagenous colitisGut, 2000